SLC5A2 and metabolic syndrome: Comparing baseline characteristics by drug type, new users of SGLT2 inhibitors were slightly younger; initiated the drug in more recent years; had smaller Hb1c level and higher BMI; were more likely to use drugs for hypertension, dyslipidemia, and hyperuricemia; and were more likely to have a history of heart failure and myocardial infarction (Table 1).